Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 mirikizumab trial in moderately to severely active Crohn's disease
NL-OMON52841Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Clinical response by PRO at Week 12 and endoscopic response at Week 52, Clinical response by PRO at Week 12 and clinical remission by CDAI at Week 52 and 2 more. Started Sep 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON52841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52841.